07.06.15
The U.S. Food and Drug Administration (FDA) has approved primary care retinal screening software made by Intelligent Retinal Imaging Systems.
As a telemedicine platform for screening patients with diabetic retinopathy, macular edema, glaucoma and other potential conditions, Intelligent Retinal Imaging Systems' (IRIS) software currently is the only FDA-cleared Class II device, according to the company.
“We are very pleased to announce this major milestone for IRIS. FDA clearance is an important differentiator about our service and underscores our commitment to go above and beyond with our technology. We have worked very hard to build scalable systems that protect patient health information and support our mission to end preventable blindness,” Jonathan Stevenson, vice president and chief information officer at IRIS, said in a news release.
The FDA approved IRIS for use in storing, managing and displaying patient data, diagnostic data and images from computerized diagnostic instruments or systems. Additionally, trained health care professionals will be able to view original and color amplified images on the web-based software system.
“IRIS has delivered a step forward in the global advancement of telemedicine technology, and is yet another validation of a system with the potential to significantly expand access for the millions of patients with diabetes who fail to receive annual retinal assessments,” Ingrid Zimmer-Galler, M.D., board member of the American Telemedicine Association, said in the news release.
Based in Pensacola, Fla., Intelligent Retinal Imaging Systems develops retinal screening services that enhance preventative care. The company works with Lions Eye Institute for Transplant & Research to provide screenings at events across the southern United States, and works closely with the Florida Institute for Human and Machine Cognition to advance healthcare technologies.
“We are very pleased to announce this major milestone for IRIS. FDA clearance is an important differentiator about our service and underscores our commitment to go above and beyond with our technology. We have worked very hard to build scalable systems that protect patient health information and support our mission to end preventable blindness,” Jonathan Stevenson, vice president and chief information officer at IRIS, said in a news release.
The FDA approved IRIS for use in storing, managing and displaying patient data, diagnostic data and images from computerized diagnostic instruments or systems. Additionally, trained health care professionals will be able to view original and color amplified images on the web-based software system.
“IRIS has delivered a step forward in the global advancement of telemedicine technology, and is yet another validation of a system with the potential to significantly expand access for the millions of patients with diabetes who fail to receive annual retinal assessments,” Ingrid Zimmer-Galler, M.D., board member of the American Telemedicine Association, said in the news release.
Based in Pensacola, Fla., Intelligent Retinal Imaging Systems develops retinal screening services that enhance preventative care. The company works with Lions Eye Institute for Transplant & Research to provide screenings at events across the southern United States, and works closely with the Florida Institute for Human and Machine Cognition to advance healthcare technologies.